• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

NINTEDANIB Drug Record

  • Summary
  • Interactions
  • Claims
  • NINTEDANIB chembl:CHEMBL502835 ApprovedAntineoplastic

    Alternate Names:

    VARGATEF
    BIBF1120
    NINTEDANIB
    OFEV
    BIBF-1120
    INTEDANIB
    METHYL (3Z)-3-[(4-{METHYL[(4-METHYLPIPERAZIN-1-YL)ACETYL]AMINO}ANILINO)(PHENYL)METHYLIDENE]-2-OXO-2,3-DIHYDRO-1H-INDOLE-6-CARBOXYLATE
    OFEV®
    VARGATEF®
    BIBF 1120
    drugbank:09079
    chembl:CHEMBL502835
    chemidplus:656247-17-5
    rxcui:1592737
    pubchem.compound:9809715

    Drug Info:

    Drug Class Kinase Inhibitors
    FDA Approval not approved
    Drug Class Small molecule
    Drug Indications antineoplastic agent
    (4 More Sources)

    Publications:

    Hilberg et al., 2008, BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy., Cancer Res.
    Wind S et al., 2019, Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib., Clin Pharmacokinet
    Gozgit et al., 2012, Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models., Mol. Cancer Ther.
    Roth GJ et al., 2009, Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120)., J Med Chem
  • NINTEDANIB   FGR

    Interaction Score: 0.49

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Notes

    PMIDs:
    None found


    Sources:
    TALC

  • NINTEDANIB   FGFR2

    Interaction Score: 0.46

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name BIBF-1120,Vargatef
    Novel drug target Established target
    Notes

    PMIDs:
    18559524 22238366 31016670


    Sources:
    TALC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial JAX-CKB

  • NINTEDANIB   CFLAR

    Interaction Score: 0.42

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    ClearityFoundationClinicalTrial

  • NINTEDANIB   FGFR3

    Interaction Score: 0.38

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Response Type resistant
    Indication/Tumor Type urinary bladder cancer
    Evidence Type Actionable

    PMIDs:
    22238366 18559524 31016670


    Sources:
    TALC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial JAX-CKB

  • NINTEDANIB   FGFR1

    Interaction Score: 0.31

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Notes
    Indication/Tumor Type Advanced Solid Tumor
    Response Type decreased response

    PMIDs:
    18559524 22238366 31016670


    Sources:
    TALC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial JAX-CKB TTD

  • NINTEDANIB   PDGFRA

    Interaction Score: 0.28

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Notes
    Trial Name BIBF-1120,Vargatef
    Novel drug target Established target

    PMIDs:
    31016670 18559524


    Sources:
    TALC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial

  • NINTEDANIB   PDGFRB

    Interaction Score: 0.25

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Notes
    Trial Name BIBF-1120,Vargatef
    Novel drug target Established target

    PMIDs:
    31016670 18559524


    Sources:
    TALC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial

  • NINTEDANIB   FLT1

    Interaction Score: 0.22

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Notes
    Trial Name BIBF-1120,Vargatef
    Novel drug target Established target

    PMIDs:
    18559524 31016670


    Sources:
    TALC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial

  • NINTEDANIB   LYN

    Interaction Score: 0.22

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Notes

    PMIDs:
    18559524 31016670


    Sources:
    TALC

  • NINTEDANIB   FLT4

    Interaction Score: 0.21

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name BIBF-1120,Vargatef
    Novel drug target Established target
    Notes

    PMIDs:
    18559524 31016670


    Sources:
    TALC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial

  • NINTEDANIB   KDR

    Interaction Score: 0.19

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name BIBF-1120,Vargatef
    Notes

    PMIDs:
    18559524 19522465 31016670


    Sources:
    TALC DTC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial

  • NINTEDANIB   LCK

    Interaction Score: 0.17

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Notes

    PMIDs:
    18559524 31016670


    Sources:
    TALC

  • NINTEDANIB   HCK

    Interaction Score: 0.16

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Notes

    PMIDs:
    None found


    Sources:
    TALC

  • NINTEDANIB   SRC

    Interaction Score: 0.16

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Notes

    PMIDs:
    18559524 31016670


    Sources:
    TALC

  • NINTEDANIB   FGFR4

    Interaction Score: 0.11

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    None found


    Sources:
    ClearityFoundationClinicalTrial

  • NINTEDANIB   FRK

    Interaction Score: 0.11

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Notes

    PMIDs:
    None found


    Sources:
    TALC

  • NINTEDANIB   FLT3

    Interaction Score: 0.1

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    18559524 31016670


    Sources:
    TTD

  • NINTEDANIB   FYN

    Interaction Score: 0.09

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Notes

    PMIDs:
    None found


    Sources:
    TALC

  • NINTEDANIB   BLK

    Interaction Score: 0.09

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Notes

    PMIDs:
    None found


    Sources:
    TALC

  • NINTEDANIB   AKT1

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18559524


    Sources:
    DTC

  • NINTEDANIB   YES1

    Interaction Score: 0.01

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Notes

    PMIDs:
    None found


    Sources:
    TALC

  • MyCancerGenome: NINTEDANIB

    • Version: 20-Jun-2017

    Alternate Names:
    BIBF1120 Development Name
    NINTEDANIB Generic Name
    VARGATEF Trade Name

    Drug Info:
    Drug Class Kinase Inhibitors

    Publications:

  • TdgClinicalTrial: NINTEDANIB

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antineoplastic agent
    Drug Class Small molecule
    FDA Approval not approved

    Publications:

  • DTC: NINTEDANIB

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL502835 ChEMBL Drug ID

    Drug Info:

    Publications:
    Hilberg et al., 2008, BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy., Cancer Res.
    Roth GJ et al., 2009, Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120)., J Med Chem

  • JAX-CKB: Nintedanib

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Gozgit et al., 2012, Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models., Mol. Cancer Ther.

  • TALC: NINTEDANIB

    • Version: 12-May-2016

    Alternate Names:
    NINTEDANIB Primary Drug Name
    VARGATEF Drug Trade Name
    BIBF 1120 Drug Synonym

    Drug Info:

    Publications:

  • TTD: Intedanib

    • Version: 2020.06.01

    Alternate Names:
    D09HNV TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL502835

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ClearityFoundationClinicalTrial: NINTEDANIB

    • Version: 15-June-2013

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21